Liquidia Technologies Inc

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The company was founded on June 28, 2020 and is headquartered in Morrisville, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Liquidia Technologies reports robust Q4 earnings, eyes YUTREPIA's market potential

Liquidia Technologies Inc (LQDA) showcased strong financial performance and promising prospects for its flagship product, YUTREPIA, in the pharmaceutical market. While facing challenges in legal proceedings and market competition, the company's focus on innovation, clinical trials, and strategic positioning bodes well for future growth and success.

Liquidia Technologies navigates legal hurdles to capitalize on YUTREPIA

Liquidia Technologies faces financial challenges with a net loss in Q1 2023 but holds a strong cash position. The success of YUTREPIA hinges on navigating legal hurdles and effectively differentiating itself in the market.

Liquidia Technologies reports solid Q2 results amidst legal victories

Liquidia Technologies Inc's Q2 2023 Earnings Call highlighted strong financials, legal victories, and strategic focus on R&D. While facing legal challenges and balancing expenses, the company remains confident in its progress. Opportunities in FDA approvals, clinical development, and strategic partnerships present avenues for growth.

Liquidia Technologies Inc (LQDA) reports strong progress and prepares for market expansion

Liquidia Technologies Inc (LQDA) made significant strides in developing inhaled treprostinil products, showcasing promising results and clear benefits.
While facing regulatory and market challenges, the company's strong commercial preparations and financial prudence position it well for future growth.
Opportunities in market expansion, successful product launches, and program development offer avenues for revenue growth and industry leadership.

Liquidia Technologies eyes FDA approval for YUTREPIA, targeting $3B market

Liquidia Technologies is poised for growth with a strong financial position and strategic focus on YUTREPIA to lead the treprostinil market.
While facing regulatory and operational challenges, the company's emphasis on addressing patient dosing effectively presents opportunities for market leadership.
The potential FDA approval of YUTREPIA post-March 31 opens doors to a $3 billion market opportunity, positioning the company for significant growth.

Liquidia Technologies reports strong Q1 performance and eyes market expansion

Liquidia Technologies Inc's Q1 2024 earnings call highlighted strong financial performance, market potential in inhaled treprostinil products, legal progress, and a focus on innovation. The company is well-positioned for commercial launch post-approval and aims to address the growing market demand for improved treatment options.

Liquidia Technologies reports Q2 results, eyes pulmonary hypertension market

Liquidia Technologies Inc reported mixed financial results for Q2 2024, with revenue of $3.7 million and a net loss.
The company's focus on YUTREPIA and L606 formulations presents promising opportunities in the pulmonary hypertension space.
Analyst inquiries highlighted key areas of interest, including product benefits, trial data, regulatory matters, and financial outlook.
With a strong cash position and ongoing FDA engagement, Liquidia is poised for potential growth and advancement in its pipeline.

Liquidia Technologies reports strong Q3 performance amidst regulatory challenges

Liquidia Technologies Inc's Q3 2024 Earnings Call highlighted strong financial performance, progress towards YUTREPIA approval, and strategic plans for product launch. Legal challenges and regulatory hurdles pose significant challenges, while opportunities for growth exist in product development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. The company was founded on June 28, 2020, and is headquartered in Morrisville, NC.

Liquidia Corporation (NASDAQ:LQDA ) Q3 2022 Earnings Conference Call November 8, 2022 9:15 AM ET Company Participants Jason Adair – Senior Vice President-Corporate Development and Strategy Roger Jeffs – Chief Executive Officer Rusty Schundler – General Counsel Mike Kaseta – Chief Financial Officer Rajeev Saggar – Chief Medical Officer Conference Call Participants Greg Harrison – Bank of America Chris Howerton – Jefferies Julian Harris – BTIG Matt Kaplan – Ladenburg Serge Belanger – Needham & Company Operator Good morning, and welcome, everyone, to the Liquidia Corporation Third Quarter 2022 Financial Results and Corporate Update Conference Call. My name is Abby, and I will be your conference operator today.

Liquidia Corporation (LQDA) Q3 2022 Earnings Call Transcript

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 22.22% and 9.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates

Company to host webcast and conference call today at 8:30 a.m. ET Company to host webcast and conference call today at 8:30 a.m. ET

Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Cyanotech

The New Board Members Will Bring Industry Experience to Contribute to Company Growth WOODINVILLE, Wash. , Nov. 2, 2022 /PRNewswire/ -- Anavasi Diagnostics ('Anavasi'), an NIH/RADx medical technology company focused on the development of novel molecular diagnostic testing, recently announced the election of three new outside members to its Board of Directors, Bryan Crane, PhD, Arthur Kirsch, and David Vied.

ANAVASI DIAGNOSTICS ANNOUNCES NEWLY ELECTED OUTSIDE BOARD OF DIRECTORS

MORRISVILLE, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.

Liquidia to Report Third Quarter 2022 Financial Results on November 8, 2022

MORRISVILLE, N.C., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on October 26, 2022, the Precedential Opinion Panel (POP) of the United States Patent and Trademark Office (USPTO) denied a request by United Therapeutics (UTC) to review the decision by the Patent Trial and Appeals Board (PTAB), which found in July 2022 through inter partes review (IPR) that all claims in U.S. Patent No. 10,716,793 (‘793 Patent) are unpatentable over certain prior art cited by Liquidia.

Precedential Opinion Panel Denies United Therapeutics' Request for Review of ‘793 Inter Partes Review Decision

MORRISVILLE, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the presentation of data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861, at the CHEST 2022 Annual Meeting hosted by the American College of Chest Physicians in Nashville, Tennessee.

Liquidia Announces Presentations at the CHEST 2022 Annual Meeting

Lazydays

Protara Therapeutics Inc

TRACON Pharmaceuticals

Mountain Crest Acquisition Corp II

L. B. Foster

LINKBANCORP Inc

Larimar Therapeutics Inc

Macerich

MFA Financial

B. Riley Financial

TransCode Therapeutics

Tilly's

Zivo Bioscience

In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market

Calumet Inc

Hudson Technologies

iRhythm Technologies

Karuna Therapeutics Inc

Lantheus Holdings

Veru

Before jumping directly into momentum stocks worth buying now, it's important to understand what momentum trading is. As the name implies, momentum trading relies on reacting to the current movement of a stock or sector.

7 Momentum Stocks to Buy Now for Extraordinary Gains

Investors were obviously cheered by a round of insider buying.

Why Liquidia Stock Rocketed Nearly 21% Higher Today

MORRISVILLE, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that a ruling was issued by Judge Andrews, who is presiding over the litigation filed by United Therapeutics Corporation (UTC) in the United States District Court for the District of Delaware under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) that alleges Liquidia infringes U.S. Patent No. 9,593,066 (‘066 Patent), U.S. Patent No. 10,716,793 (‘793 Patent) and U.S. Patent No. 9,604,901 (‘901 patent).

Liquidia Provides Update on Hatch-Waxman Litigation and to Host Call on September 1, 2022, at 8:00am E.T.

Here is how Liquidia Technologies, Inc. (LQDA) and PolyPid Ltd. (PYPD) have performed compared to their sector so far this year.

Is Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year?

The mean of analysts' price targets for Liquidia Technologies, Inc. (LQDA) points to a 136.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 136%: Here's is How to Trade

Sunopta

We used one of our Zacks screens to help show investors how to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying as we start to close out August.

Find Highly-Ranked Cheap Stocks Under $10 to Buy with this Screen

Does Liquidia Technologies, Inc. (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Liquidia Technologies, Inc. (LQDA) is a Great Momentum Stock to Buy

Optimism by the company regarding a patent ruling is encouraging investors.

Why Liquidia Shares Rose 18.4% on Monday

The average of price targets set by Wall Street analysts indicates a potential upside of 74.1% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 74%: Here's is How to Trade

Liquidia Corporation (NASDAQ:LQDA ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Jason Adair - Senior Vice President, Corporate Development and Strategy Roger Jeffs - Chief Executive Officer Dr. Rajeev Saggar - Chief Medical Officer Rusty Schundler - General Counsel Mike Kaseta - Chief Financial Officer Conference Call Participants Greg Harrison - Bank of America Serge Belanger - Needham & Company Matt Kaplan - Ladenburg Thalmann Julian Harrison - BTIG Operator Good morning. And welcome everyone to the Liquidia Corporation Second Quarter 2022 Financial Results and Corporate Update Conference Call.

Liquidia Corporation's (LQDA) CEO Roger Jeffs on Q2 2022 Results - Earnings Call Transcript

MORRISVILLE, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the second quarter ended June 30, 2022. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the second quarter 2022 financial results and provide a corporate update.

Liquidia Reports Second Quarter 2022 Financial Results and Provides Corporate Update

MORRISVILLE, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2022 financial results on Thursday, August 11, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.

Liquidia to Report Second Quarter 2022 Financial Results on August 11, 2022

MORRISVILLE, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the publication of clinical data from the completed INSPIRE study evaluating YUTREPIA™ (treprostinil) inhalation powder, formerly known as LIQ861, in patients with pulmonary arterial hypertension (PAH) in the journal Pulmonary Circulation.

Liquidia Announces the Publication of Long-Term Clinical Data from Completed INSPIRE Study in the Journal Pulmonary Circulation

MORRISVILLE, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will be participating at the following investor conferences next week:

Liquidia to Participate in Upcoming Investor Conferences

MORRISVILLE, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for 2,000 shares of Liquidia's common stock to a newly hired non-executive employee under the Liquidia Corporation 2022 Inducement Plan (the “Inducement Plan”). The stock option was granted as an inducement material to the grantee's acceptance of employment with Liquidia (or one of its subsidiaries) as a component of the grantee's employment compensation in accordance with Nasdaq Listing Rule 5635(c)(4).

Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

MORRISVILLE, N.C., July 19, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes Review (IPR) proceeding against U.S. Patent No. 10,716,793 (‘793 patent) owned by United Therapeutics Corporation (UTC) and listed in the Orange Book for Tyvaso® (treprostinil inhalation solution). In its ruling, the PTAB found that, based on the preponderance of the evidence, all the claims of the '793 patent have been shown to be unpatentable.

Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent

MORRISVILLE, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the company was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on June 27, as part of the 2022 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. The stock also was automatically added to the appropriate growth and value indexes.

News for Liquidia Technologies Inc Stock (LQDA)